2013
DOI: 10.1007/s10792-013-9879-3
|View full text |Cite
|
Sign up to set email alerts
|

Peripheral ulcerative keratitis as the presenting feature of systemic rheumatoid vasculitis without joint involvement

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
9
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(9 citation statements)
references
References 11 publications
0
9
0
Order By: Relevance
“…However, anticyclic citrullinated peptide antibodies (anti-CCP antibodies) are more sensitive than RF, and they are special markers of systemic involvement in RA [50]. Compared with RF, anti-CCP appears to be related to increased and worse ocular manifestation in RA [51]. More recently, other posttranslational modifications (PTMs) associated with RA have been found to include remarkable antibodies [45].…”
Section: Rheumatoid Arthritismentioning
confidence: 99%
“…However, anticyclic citrullinated peptide antibodies (anti-CCP antibodies) are more sensitive than RF, and they are special markers of systemic involvement in RA [50]. Compared with RF, anti-CCP appears to be related to increased and worse ocular manifestation in RA [51]. More recently, other posttranslational modifications (PTMs) associated with RA have been found to include remarkable antibodies [45].…”
Section: Rheumatoid Arthritismentioning
confidence: 99%
“…One case presented with RV as a primary symptom, and the disease duration was two (5). The other case presented with ulcerative keratitis as the feature of RV without joint involvement (6). These cases show that RV may occur in new-onset RA or without joint involvement, and the disease duration or progression of RA may vary.…”
Section: Discussionmentioning
confidence: 84%
“…43 Peripheral ulcerative keratitis develops in chronic HCV infection, with associated necrotising scleritis being a common clinical finding. 44,45,46,47,48,49 The management of choice for HCV infection is interferon-alpha and ribavirin. 43 The patients who were refractory to this have responded well to a combination of interferon-alpha, ribavirin and rituximab.…”
Section: Hepatitis Cmentioning
confidence: 99%